NeuroOne Expands Global Patent Portfolio with Key Approvals for Neurological Medical Devices

NeuroOne Medical Technologies Corporation has significantly expanded its intellectual property portfolio with recent patent approvals from both the United States and European patent offices, positioning the company for broader technological development and market expansion in neurological medical devices. The medical technology company, which focuses on improving surgical care for patients with neurological disorders, announced three key patent developments that cover innovative electrode technologies and manufacturing methods.

The United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application 17/860,232 on September 29, 2025, covering novel electrode devices with temperature sensors. This technology is particularly significant as temperature control serves as a critical safety feature in the company's OneRF Ablation System for brain ablation procedures in patients suffering from seizures. A Notice of Allowance indicates the USPTO's determination that a patent should be granted following examination, with formal issuance expected in the coming months.

On October 1, 2025, the European Patent Office granted European Patent 4013481, titled "Spinal Cord Stimulation Systems, Methods, and Devices," marking NeuroOne's first European patent. This patent covers novel spinal cord stimulation devices featuring a deployable electrode array body. According to CEO Dave Rosa, this technology represents a significant advancement as it features "our percutaneously placed paddle electrode, designed to save patients from having to undergo a surgical incision to treat lower back pain."

The company received additional validation on October 7, 2025, when the USPTO issued U.S. Patent 12,435,407 covering novel methods for manufacturing neural probe and spinal cord stimulation devices. This patent includes specific processes for arranging probe components and depositing electrode contact material, potentially enhancing production efficiency and device performance.

These recent additions complement NeuroOne's existing portfolio, which includes four additional issued U.S. patents, seven pending U.S. applications, and eight pending foreign applications covering various thin-film electrode technologies. The expanded portfolio covers both neural and spinal cord electrodes with unique structures designed to optimize functionality while minimizing device profiles.

The importance of these patent developments extends beyond corporate intellectual property protection. For patients suffering from neurological conditions such as epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain, these technological advancements could lead to improved treatment options with potentially better outcomes and reduced procedural costs. The temperature-sensing electrode technology addresses critical safety concerns in brain ablation procedures, while the minimally invasive spinal cord stimulation devices could reduce surgical trauma for chronic pain patients.

From an industry perspective, NeuroOne's growing patent portfolio signals the company's commitment to expanding its technology platform into broader applications and use cases. The European patent grant opens potential market expansion opportunities in European healthcare systems, while the manufacturing method patent could streamline production processes. The company's focus on developing minimally invasive and high-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation positions it at the forefront of neurological medical technology innovation.

Dave Rosa emphasized the strategic importance of these developments, stating that "NeuroOne has made tremendous progress expanding our robust patent portfolio. Our goal is to continue to grow our technology platform to broader use cases and applications." The company's technology platform may eventually expand to address additional medical conditions including depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence applications, though such expansions remain subject to regulatory approvals and clinical validation.